Robbie McLaren

Mr. McLaren's experience includes advising:

Life Sciences and Healthcare

M&A

• Abcam, a global leader in the supply of life science research tools on its:
  • US$5.7bn sale to Danaher Corp
  • US$340 million acquisition of BioVision
  • License and asset purchase agreement with Roche Tissue Diagnostics to obtain exclusive rights to the product portfolio of Spring Bioscience Corporation
• Baxter International Inc., in connection with its US$625 million acquisition of Claris Injectables Limited, an India-based manufacturer of sterile injectables
• BenevolentAI, a UK-based clinical-stage AI drug discovery company, on its business combination with Odyssey Acquisition S.A., a special purpose acquisition company 
• Zogenix on its acquisition of Brabant Pharma, a UK-based pharmaceutical company
• Watson Pharmaceuticals / Actavis / Allergan on its:
  • €4.25 billion acquisition of the Actavis Group, making Watson the third-largest global generics company
  • US$8.5bn acquisition of Warner Chilcott, an Ireland-based pharmaceutical company 
  • Divestment of part of its Western European generics sale and marketing business to Aurobindo
  • US$40.5 billion sale of its global generics pharmaceuticals business to Teva
• Atnahs Pharma (now Pharmanovia) on its acquisition of assets related to five hypertension medicine brands from AstraZeneca
• GlaxoSmithKline on its:
  • disposal of its Prevacid®24HR business to Perrigo Company
  • sale of assets relating to four established OTC brands, being Baldriparan and Formigran, Spalt and Kamol to PharmaSGP, a German pharmaceutical company
  • Rayner Surgical Group, a UK-based developer and manufacturer of intraocular lenses, on its sale to CVC Capital Partners

Private Equity

• Patient Square Capital on its investment in Apollo Therapeutics, a UK and US-based drug discovery company 
• Norgine, a Netherlands-based specialty pharmaceutical company, on its US$2 billion sale to Goldman Sachs
• TPG on the acquisition of a majority interest in DOC Generici, a leading generic pharmaceutical company based in Milan, from ICG and Merieux Equity Partners
• Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with its:
  • US$703 million acquisition by CVC Capital Partners of women’s healthcare assets from Teva Pharmaceutical Industries Ltd
  • Acquisition of certain pharmaceutical products from Janssen
  • Sale to a consortium controlled by Carlyle and PAI
• Nordic Capital on:
  • the US$846 million acquisition of ADVANZ PHARMA, a specialty pharmaceutical company
  • the acquisition by Acino, a portfolio company, of various pharmaceutical products and related assets in the NEMEA region from Takeda
• Novo Holdings A/S on its:
  • investment into Freeline Therapeutics, a clinical-stage biotechnology company
  • investment in Hummingbird, a biotechnology company 
  • investment into Quanta Dialysis Technologies
  • investment into Adaptimmune, a leading biotechnology company
  • £230 million disposal of Archimedes
  • US$800 million acquisition of Xellia
  • £400 million acquisition of BBI Group 
• BC Partners on the acquisition of a majority interest in the complex generic medicines business of Synthon International, a Netherlands-based multinational pharmaceutical company
• The shareholders of Pharmathen SA, a Greek pharmaceuticals company, on their sale of a controlling interest in Pharmathen to BC Partners

Technology, Media, and Telecoms

• Rivulis, a portfolio company of Temasek, on the acquisition of the international business of Jain Irrigation Systems, an India-based micro irrigation systems company
• Darktrace, a UK-based AI cyber security company, in connection with:
  • its £1.7 billion initial public offering and listing on the London Stock Exchange
  • acquisition of Cybersprint, a Netherlands-based cybersecurity firm
  • a convertible note round led by KKR and Summit Partners
• Vertical Aerospace on its US$2.2 billion business combination with Broadstone Acquisition Corp., a special purpose acquisition company
• Centricus Acquisition Corp, a special purpose acquisition company, on its US$1 billion business combination with Arqit, a London-based developer of a quantum encryption platform
• Canva, an Australia-based online graphic design and publishing company, on its acquisition of Kiln Enterprises, a data visualization company
• Mimecast on the acquisition of Simply Migrate, a London-based provider of archive data migration technology
• Telenor on its €2.8 billion sale of its assets in Central and Eastern Europe (CEE) to PPF Group

Emerging Companies

• Moneybox, the leading digital wealth manager, on its £35 million Series D funding round
• Osler Diagnostics, a health technology company, on its Series C financing round
• Bloom and Wild on its:
  • Series C financing round
  • Acquisition of Bergamotte, a French online florist
  • Acquisition of Bloomon, a Netherlands-based online florist
• Carbon Clean, a global leader in cost-effective industrial carbon capture on the investment made by Chevron, one of the world’s leading integrated energy companies
• Burda on their:
  • Series C investment in HungryPanda Ltd
  • Series B and Series B1 financing of Bloom & Wild, an online flower delivery platform
  • Series A financing of Bleach
• An Asian investor on their equity investment in:
  • Sound Cloud, a Germany-based company engaged in providing online audio platform services
  • Claroty, a cybersecurity software company
  • Common Sense Robotics
  • South Pole, a Swiss carbon finance consultancy
  • Aerogen, an acute aerosol drug delivery business
  • Secret Escapes, a luxury travel company
  • Snyk Limited, a cybersecurity company
  • Sum-up, a global financial technology company